Optimizing screening and management of cardiovascular health in prostate cancer: A review

  • Miran Kenk Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON
  • Jean C. Grégoire Montreal Heart Institute, Montreal, QC
  • Marc-Andre Coté Centre hospitalier universitaire de Quebec 1050 ch Sainte-Foy Québec QC G1S 4L8
  • Kim A. Connelly St. Michael's Hospital Li Ka Shing Knowledge Institute 30 Bond St. Toronto, ON M5B 1W8
  • Margot K. Davis The University of British Columbia Diamond Health Care Center 2775 Laurel St 10th Floor Vancouver, BC V5Z 1M9
  • George Dresser Division of Clinical Pharmacology Department of Medicine Western University London, Ontario, Canada
  • Nina Ghosh Queensway Carleton Hospital University of Ottawa Heart Institute, Ottawa, ON
  • Shaun Goodman Division of Cardiology, St. Michael's Hospital, Toronto, ON
  • Christopher Johnson Christopher Johnson, MD, FRCPC Division of Cardiology University of Ottawa Ottawa, ON
  • Neil Fleshner Princess Margaret Hospital, Toronto, ON
Keywords: androgen deprivation therapy, cardiovascular risk, prostate cancer

Abstract

In clinical practice, cancer management does not consistently encompass screening and identification of cardiovascular (CV) risk. The use of androgen deprivation therapy (ADT) in prostate cancer has been associated with increased CV risk and development of metabolic syndrome, necessitating identification of patients at risk in this population (e.g., those with pre-existing CV disease). A multidisciplinary team of Canadian physicians was assembled to develop a series of recommendations intended to identify patients who may benefit from optimal management of their CV disease and/or modification of cardiac risk factors. A key goal was the development of a simple screening tool for identification of patients with pre-existing CV disease. This simple and inclusive set of recommendations are intended for use within urology clinics to facilitate holistic approaches and simplify the management of patients.

Published
2020-06-01
How to Cite
Kenk, M., Grégoire , J., Coté, M.-A., Connelly, K. A., Davis, M. K., Dresser, G., Ghosh, N., Goodman, S., Johnson, C., & Fleshner, N. (2020). Optimizing screening and management of cardiovascular health in prostate cancer: A review. Canadian Urological Association Journal, 14(9), E458-64. https://doi.org/10.5489/cuaj.6685